Get the Stockscreener App
18.59
1.48%
-0.28
Anaptysbio Inc stock is traded at $18.59, with a volume of 661.10K.
It is down -1.48% in the last 24 hours and up +10.13% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$18.87
Open:
$19.05
24h Volume:
661.10K
Relative Volume:
0.73
Market Cap:
$565.67M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-3.0576
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
-12.39%
1M Performance:
+10.13%
6M Performance:
-50.79%
1Y Performance:
-27.07%
1-Day Range:
$18.08
$19.16
1-Week Range:
$18.08
$21.57
52-Week Range:
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
18.59 | 565.67M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7%What's Next? - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Update - MarketBeat
Q1 Earnings Forecast for AnaptysBio Issued By HC Wainwright - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Down 8.6% in January - Defense World
What is HC Wainwright’s Forecast for AnaptysBio Q1 Earnings? - Armenian Reporter
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $51.00 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Up 16.5% After Analyst Upgrade - MarketBeat
Q1 Earnings Estimate for AnaptysBio Issued By HC Wainwright - Defense World
AnaptysBio (NASDAQ:ANAB) Given New $51.00 Price Target at Wells Fargo & Company - Armenian Reporter
Wedbush Reiterates Outperform Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
Wedbush Reaffirms Outperform Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? - MSN
AnaptysBio price target raised to $22 from $19 at H.C. Wainwright - MSN
When the Price of (ANAB) Talks, People Listen - Stock Traders Daily
Wells Fargo & Company Boosts AnaptysBio (NASDAQ:ANAB) Price Target to $51.00 - Defense World
What Analysts Were Expecting After AnaptysBio Inc (NASDAQ: ANAB) rose 19.44% - Stocks Register
AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected - Simply Wall St
Positive Outlook on AnaptysBio: Buy Rating Based on Undervaluation and Promising Pipeline - TipRanks
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral By Investing.com - Investing.com Canada
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data - Yahoo Finance
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral - MSN
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? - Yahoo Finance
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment - MSN
Rosnilimab shows promise in rheumatoid arthritis trial By Investing.com - Investing.com Canada
Rosnilimab shows promise in rheumatoid arthritis trial - MSN
Vanda and AnaptysBio link for generalised pustular psoriasis therapy - MSN
Anaptys stock surges on trial readout (update) (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio rockets on rosnilimab data - The Pharma Letter
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial - Yahoo Finance
AnaptysBio climbs on arthritis drug trial data - TradingView
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday - Benzinga
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial - Fierce Biotech
AnaptysBio stock soars on positive RA trial results - MSN
AnaptysBio Announces Promising Phase 2b RENOIR Trial Results - TipRanks
Anaptys Announces Rosnilimab Achieves Positive Results in Ra Phase 2B Trial and Highest Ever Reported Cdai Lda Response over 6 Months - Marketscreener.com
Anaptys surges as arthritis therapy succeeds in mid-stage trial - MSN
AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise - Marketscreener.com
Anaptys stock surges on trial readout (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio stock soars on positive RA trial results By Investing.com - Investing.com Australia
Anaptys Announces Rosnilimab Achieved Positive Results In RA Phase 2B Trial -February 12, 2025 at 07:44 am EST - Marketscreener.com
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months - The Manila Times
AnaptysBio announces Phase 2b RENOIR trial met primary endpoint - TipRanks
Anaptys Announces Rosnilimab Achieved Positive Results in - GlobeNewswire
Rosnilimab Phase 2b Trial Achieves Record-Breaking 69% Response Rate in Rheumatoid Arthritis | ANAB Stock News - StockTitan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
AnaptysBio (ANAB) Stock Sees Strong Gains In Extended Session - Stocks Telegraph
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anaptysbio Inc Stock (ANAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
Dec 30 '24 |
Buy |
12.92 |
65,184 |
842,060 |
7,860,180 |
| EcoR1 Capital, LLC | Director |
Dec 31 '24 |
Buy |
12.93 |
13,268 |
171,513 |
7,873,448 |
| EcoR1 Capital, LLC | Director |
Jan 02 '25 |
Buy |
12.95 |
6,646 |
86,070 |
7,880,094 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Option Exercise |
6.93 |
10,000 |
69,300 |
11,950 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Sale |
25.00 |
10,000 |
250,000 |
1,950 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):